Browse studies

Find your next paid study

1 recruiting study matching your filters

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (…

Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis

Blueprint Medicines CorporationNCT04910685